Biovica records another quarter of modest quarterly IVD test sales growth of 50-55% (compared with the previous quarter), with improving prospects ahead. The IVD growth is high, but Biovica must dramatically elevate recurring sales to break even by late 2025. Pharma RUO-related sales are also growing in the number of projects, prospects, and sales, albeit at a moderate pace in actual numbers. The financial pressure has eased after the recent direct share/warrant issue, but the pressure is on to reach a quarterly sales level approaching SEK 35m.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/